A phase 1 clinical trial of peptide-pulsed monocyte-derived dendritic cell vaccination to expand adoptively transferred cytomegalovirus -specific cytotoxic T lymphocytes after allogeneic stem cell transplantation

This study is testing a new approach to prevent a dangerous virus called cytomegalovirus (CMV) in patients who have received a stem cell (bone marrow) transplant. CMV can cause serious illness after a transplant when the immune system is very weak. The study uses two types of immune cells taken from the transplant donor — T lymphocytes and dendritic cells — and gives them back to the patient as a kind of vaccine to help rebuild the immune system's ability to fight CMV. You may be eligible if: - You are a transplant recipient receiving a blood stem cell (bone marrow) transplant - Both you and your donor are HLA-A2 positive (a specific immune system marker) - Your donor has been previously exposed to CMV (CMV seropositive) - Your transplant is a full or one-antigen-mismatched match from your donor You may NOT be eligible if: - Your donor is HLA-A2 negative - Your donor has never been exposed to CMV (CMV seronegative) Talk to your doctor about whether this trial might be right for you.